Ind-Swift

We, Ind-Swift, would like to introduce ourselves as US$ 200 million fully integrated global pharmaceutical group. The group is recognized as a front-runner in introduction of advanced bulk actives and has established a strong reputation in the Indian pharmaceutical industry.

Ind Swift Laboratories Limited (ISLL), an ISO 9001-2000 company based at Chandigarh, India is a part of the Ind-Swift group. ISLL is a research driven pharmaceutical company and maintains state-of the art environment friendly manufacturing facilities. It is primarily engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. Our strength in organic synthetic chemistry has resulted in the company emerging as the pioneer for a number of products both in the National and International markets. As the company built up vast skills in the area of research and development, quality systems as well as matters relating to regulatory compliance, it has established presence in more than 40 partial and regulated markets of the world.

ISLL is one of the largest manufacturer and exporter of Macrolide Antibiotics worldwide and enjoys leadership position in Clarithromycin, Clarithromycin Granules, Azithromycin, Roxithromycin and Roxithromycin Granules.

Amongst the top 20 blockbuster drugs within the industry today, ISLL is manufacturing many such molecules I. E. Fexofenadine Hydrochloride, Clopidogrel Hydrogen Sulphate, Clarithromycin, Atorvastatin Calcium, Pioglitazone etc.

The company has a full-fledged R&D center, for developing new drug delivery system, non-infringing processes, custom synthesis, process developments and manufacturing of customer's own discovery product, which has given us desired impetus for continuing growth over the years. Our Formulation Division has been granted US patent for its controlled dosage form of macrolide anti-infective NDDS drug, Clarithromycin.

The company has already filed two new patents and its research R&D division is in the process of developing non-infringing processes for 4-6 molecules. We are in discussions with several companies who are willing to file their Abbreviated New Drug Applications (ANDAs) supported by our DMF filed with USFDA.

We have already filed our common technical documents (CTD) for Clarithromycin with the USFDA and two CTD's with European authorities. The company is ready for the accreditation of US-FDA and employs current Good Manufacturing Practices (cGMP), which are recognized and accepted in the stringent regulated markets. This also includes a responsible commitment to the safety, health and environment (She).